Gilead Sciences Q1 earnings report is due April 24. Explore forecasts on revenue growth, EPS expectations, HIV pipeline ...

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

As previously reported, Cantor Fitzgerald analyst Carter Gould upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, ...

The medicine, lenacapavir, made by Gilead Sciences, has caused a stir because clinical trial data showed a single set of injections every six months could provide virtually complete protection ...

Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, ...